Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28949295 | 0.88 | ERN1 (0.52) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL30217843 | 0.88 | ERN1 (0.52) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL207592 | 0.76 | ERN1 (0.47) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL408055 | 0.76 | PTGDR2 (0.51) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL29377196 | 0.76 | PTGDR2 (0.51) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL3040456 | 0.73 | ERN1 (0.64) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL30037767 | 0.72 | ERN1 (0.57) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL29525291 | 0.72 | ERN1 (0.57) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL18699 | 0.72 | ERN1 (0.57) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL414267 | 0.72 | ERN1 (0.61) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197551-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-12-28 | — | — | EP | disclosed |
| US-8455638-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A2, GUCY1A1 | ERN1 474/4885CYP2A6 3384/4885PTGDR2 443/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | ERN1 474/4885CYP2A6 3384/4885PTGDR2 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.